Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World January 8, 2016 Rebecca Trager	DuPont cuts go deep in Delaware Just after confirming that it will merge with Dow then split into three, US chemicals heavyweight DuPont said it would lay off 10% its global workforce under a restructuring plan for 2016.
Chemistry World March 2009 Derek Lowe	Column: In the pipeline The author worries that mergers are upsetting the balance of the pharmaceutical ecosystem
The Motley Fool April 19, 2006 Brian Gorman	Pfizer Inches Forward The pharma continues on cost-cutting and gives back to shareholders, but R&D productivity remains a tough challenge.
Chemistry World December 16, 2015 Anthony King	Dow and DuPont mega-merger heralds break-up of giants Chemical industry giants Dow Chemical and DuPont are to merge in a $130 billion deal. The merged company will then split.
Chemistry World February 4, 2010 Matt Wilkinson	More pharma R&D budget cuts GlaxoSmithKline (GSK) and Pfizer are both following AstraZeneca's lead in cutting their research and development budgets.
Chemistry World November 27, 2015 Anthony King	Pfizer and Allergan agree mega-merger The deal is being positioned as Irish-based Allergan taking over Pfizer, with the merged entity resident in Ireland for tax purposes.
The Motley Fool February 22, 2005 Rich Duprey	Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%.
Chemistry World May 29, 2014 Derek Lowe	Messy megamergers There is a good deal to be said about drug company mergers in general.
Bio-IT World December 10, 2002 Jim Hall	21st Century R&D Strategy: Atlantic or Pacific? The biopharmaceutical sector is divided by two strategic perspectives.
Pharmaceutical Executive June 9, 2014 Cliff Kalb	The Urge to Merge Deal making lessons for pharmaceutical companies from history's storyboard.
The Motley Fool March 26, 2009 Brian Orelli	Big Pharma's R&D Model Is Broken Bigger isn't always better.
The Motley Fool October 1, 2009 Robert Steyer	For Drugmakers, It's All In or Get Out The Solvay-Abbott deal illustrates why conglomerates are getting out of the prescription-drug business.
Chemistry World February 18, 2010 Matt Wilkinson	Merck joins the cost-cutting crowd Following its merger with Schering-Plough, US drug giant Merck & Co. has announced a 'merger restructuring plan' that in its first phase will see 17,500 jobs cut.
Chemistry World March 2007 Derek Lowe	Opinion: In the Pipeline Do the benefits of pharmaceutical company mergers really outweigh the costs?
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
Chemistry World March 13, 2009 Sarah Houlton	Mega mergers sweep pharma industry Just six weeks after Pfizer agreed to buy Wyeth, US pharma companies Merck & Co. and Schering-Plough announced they are to merge.
Chemistry World March 25, 2015 Dennis Lendrem	Be careful what you wish for There is a big debate right now in the pharmaceutical industry, and specifically about measuring R&D productivity. It all comes down to a choice of metrics.
The Motley Fool July 22, 2009 Robert Steyer	Canaries in the Drug Coal Mine Contract research organizations like Pharmaceutical Product Development and ICON reflect an ailing drug industry.
Chemistry World June 2009 Derek Lowe	Column: In the pipeline The author wonders about pharmaceutical companies' motives for collaboration
The Motley Fool July 20, 2005 Stephen D. Simpson	Pfizer's Long Road Back It took time for Pfizer to reach a trough and it will take time to climb out. But over the long haul this could prove to be a solid pick.
Chemistry World March 2011 Bea Perks	Editorial: At the forefront The news that most of Pfizer's 2400 employees at Sandwich, U.K. will be made redundant over the next two years was met with surprise, disappointment and anger.
Chemistry World April 2009 Bibiana Campos-Seijo	Editorial: All change The current news seem to be - again! - dominated by the pharmaceutical industry, we can discuss the latest 'trend' in this sector, mergers and acquisitions. Indeed, M&A has become the latest fad in the pharma catwalk.
CIO October 31, 2011 Maryfran Johnson	How Pfizer's CIO Led a Transformation of the Business Pharmaceutical giant Pfizer is using IT to drive new business.
Chemistry World May 14, 2014 Andy Extance	Pfizer presses hard for AstraZeneca deal US pharma giant Pfizer is battling a backlash of suspicion and hostility across the world over its attempts to acquire its UK-headquartered rival AstraZeneca.
Chemistry World October 1, 2008 Victoria Gill	GSK to Cut 850 R&D Jobs GlaxoSmithKline has announced that up to 850 R&D jobs will be cut as it implements its new business strategy.
The Motley Fool April 27, 2004 Alyce Lomax	DuPont Doesn't Shock Here comes more good news from the chemical company.
The Motley Fool February 10, 2006 Brian Gorman	Pfizer in Pflux The company is working on its transition, but things still look fairly murky for investors.
The Motley Fool December 18, 2009 Brian Orelli	2009: The Year Pharma Learned to Love Itself While anything is possible, don't expect too much more consolidation of major drugmakers in 2010 and beyond.
The Motley Fool October 20, 2006 Brian Lawler	Pfizer Keeps Fighting If Pfizer's management can succeed on its cost-savings initiatives and maintain the high single digits of earnings-per-share growth that it expects in 2007-2008, then Pfizer may make a good investment for those willing to wait for the company's new drugs to bring back higher growth.
The Motley Fool April 5, 2005 Stephen D. Simpson	Pfizer Pfaces Its Pfuture Analysts and investors seem happy with Pfizer's long-term strategy. Should they be?
Chemistry World April 29, 2014 Phillip Broadwith	Pfizer courts AstraZeneca megamerger US-based pharma behemoth Pfizer has publically announced its intention to make a merger offer to the UK's AstraZeneca, in a deal valued at around $100 billion.
Chemistry World March 24, 2015 Phillip Broadwith	Measuring up If pressure from investors increases companies' focus on the ongoing process of reflection, renovation and transformation, then they will emerge stronger from their scuffles.
CIO October 28, 2011 Kim S. Nash	Challenging Times for Pfizer As drug patents expire, the pharmaceutical giant is investing in technology and emerging markets while cutting back on R&D and labor.
Information Today August 11, 2015	Thomson Reuters Rolls Out Pharmaceutical R&D Factbook The 2015 CMR International Pharmaceutical R&D Factbook shows global R&D trends for the biopharmaceutical industry.
IEEE Spectrum December 2005 Hira & Goldstein	R&D 100 Automakers top the list, drug companies trim back, and telecoms continue to gut their research budgets.
The Motley Fool October 26, 2011 David Lee Smith	You Can't Ignore the Strength at DuPont DuPont's combination of solid management and innovation is building a solid record.
The Motley Fool July 10, 2008 David Lee Smith	Buffett's Rohming, Too Dow's paying up for Rohm & Haas, but the deal looks good.
IndustryWeek January 1, 2009 Jill Jusko	R&D Spending: By the Numbers While the software industry spends 13.6% on R&D as a percentage of sales, the chemicals and energy sector spends only 1%.
The Motley Fool January 19, 2006 Stephen D. Simpson	Pfizer: Less Bad Is Good Enough Pfizer's quarter wasn't strong, but it was better than expected. The company may not be able to recapture past glories, but the stock is still good idea for long-term.
Pharmaceutical Executive March 1, 2009 Walter Armstrong	Attack of the Monster Merger Just when you thought it was safe to go back into M&A, the mega merger returns. What's right about Pfizer-Wyeth, and what's scary.
The Motley Fool May 20, 2011 Anupama Pattanaik	Danisco and DuPont: A Delicious Duet? What chemicals and food ingredients have in common.
IndustryWeek June 23, 2010	By The Numbers -- The Expense of R&D Among U.S.-owned businesses and U.S. affiliates of foreign companies, much of the R&D remained in the United States.
Chemistry World July 28, 2014 Andy Extance	Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover.
Chemistry World December 6, 2013 Emily James	Dow shakes out chlorine business Dow Chemical has unveiled plans to sell its chlorine business assets -- worth a total of $5 billion in annual revenue -- to make room for future spending.
The Motley Fool August 27, 2011 Michael Olsen	Rising Star Buy: More Icon Icon shares might not appreciate tomorrow, and they might decline more before they go up. But here is a rare value: a secular growth story at a stellar valuation.
Chemistry World June 11, 2008 James Mitchell Crow	GSK Job Cuts Hit Chemists GlaxoSmithKline is cutting the jobs of hundreds of scientists as it restructures its drug R&D operations.
The Motley Fool July 27, 2011 Michael Olsen	Rising Stars Buy: Icon Icon, the fourth-largest CRO, sits among the global elite and makes for a healthy investment.
The Motley Fool November 18, 2004 Salim Haji	A Misguided Merger Without clear strategic synergies, the recently announced merger between Sears and Kmart is likely to destroy shareholder value.
The Motley Fool December 3, 2008 David Lee Smith	Dow Chemical's Nimble New Moves With its Kuwait venture saved and a solid acquisition, Dow Chemical is one to keep an eye on.
The Motley Fool February 26, 2010 Brian Orelli	Drug Company Cost Cuts: Careful What You Wish For Research and development is the lifeblood of future revenue.